NOVONIX ceased 460,452 NVXAD performance rights after the conditions attached to them were not satisfied or became incapable of satisfaction. The change matters to investors because the company’s post-cessation Capital includes 997,852,692 ordinary shares and 20,729,515 remaining performance rights, alongside other unquoted securities.

Key Highlights

  • NOVONIX reported cessation of 460,452 NVXAD performance rights.
  • The cessation took effect on September 18, 2026, with no consideration paid.
  • Post-change Issued Capital includes 997,852,692 quoted ordinary fully paid shares.

The rights lapsed because their conditions were not met or could no longer be met. The cessation date was September 18, 2026.

460,452 Performance Rights Cease The securities were unquoted performance rights.

NOVONIX said the lapse involved employee performance rights following cessation of employment, and no consideration was paid for the cessation. The company’s post-change issued capital comprises 997,852,692 ordinary fully paid shares quoted on ASX. Unquoted securities following the change include 20,729,515 performance rights, 14,016,667 Options expiring on various dates and at various prices, and 1,371,566 share rights. The same capital listing includes 45,221,586 convertible notes and 35,000,000 convertible debentures. The stated figures are used in calculating the total Market Capitalisation published by ASX from time to time.